Form 4: TScan Therapeutics CFO Granted 350,000 Stock Options

TScan Therapeutics' Chief Financial Officer, Jason Amello, was granted 350,000 stock options with an exercise price of $1.12 per share.

Summary

• Jason Amello, Chief Financial Officer of TScan Therapeutics, Inc. (TCRX), was granted 350,000 stock options.
• The stock options have an exercise price of $1.12 per share.
• The transaction date for this grant was January 20, 2026.
• The options will vest with respect to 25% of the shares on the one-year anniversary of January 20, 2026 (January 20, 2027).
• The remaining balance of the options will vest in equal monthly installments over the subsequent 36 months.
• Vesting is contingent upon Mr. Amello's continued service to the Issuer on each vesting date.
• The expiration date for these stock options is January 20, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, but it is a routine compensation matter rather than a significant operational or financial announcement.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule encourages continued service and commitment from a key executive.

Future Outlook

The vesting schedule for the stock options, extending over 36 months after an initial one-year cliff, indicates an expectation of continued service from the Chief Financial Officer, Jason Amello, through at least January 2030.

Industry Context

The grant of stock options is a standard practice in the biotechnology and pharmaceutical industries to compensate and incentivize key executives. Such grants are typically tied to performance and retention, aligning executive interests with long-term company growth and shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages in the biotech sector frequently include significant equity components, such as stock options, to attract and retain top talent.
• The vesting schedule, with a one-year cliff and subsequent monthly vesting over three years, is a common structure designed to ensure long-term commitment and align executive incentives with sustained company performance, similar to practices observed at comparable early-stage biotech firms.

Stakeholder Impact

• Shareholders: The grant aims to align the CFO's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: May signal stability in executive leadership, potentially boosting morale and confidence.

Next Steps

• The stock options will begin vesting on January 20, 2027, with 25% of the shares.
• Subsequent vesting will occur in equal monthly installments over the following 36 months, subject to continued service.

Key Dates

Keywords

TScan Therapeutics, TCRX, Stock Options, Executive Compensation, Insider Transaction, Form 4, Jason Amello, Chief Financial Officer, Biotechnology